Nicole Junkermann, NJF Capital founder, presents Owkin, an AI medical research start-up whose mission is to use machine learning to develop better drugs for patients.
Staining cells so that they can be more easily identified has been a vital step in diagnosing diseases like cancer for more than a century.
Recent tech advancements have made it possible to virtually stain cells, significantly reducing cost and sample preparation time.
Medical research startup Owkin has used AI to develop a Virtual Staining generative model that can quickly and accurately unveil rich information.
Through the software available on its platform, Owkin aims to create an environment for all virtual stains used in medical research.
This innovation will transform how histopathologists work, substituting many of their tasks to a trained neural network.
Virtual Staining removes the need for a medical lab, making it particularly useful in developing countries or where resources are limited.